Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma.
We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.
Niitsu
Nozomi
N
Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan. nniitsu@saitama-med.ac.jp
Okamoto
Masataka
M
Nakamine
Hirokazu
H
Hirano
Masami
M
D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D001943:Breast Neoplasms / Q000473:pathology*; D018956:CD5 Antigens / Q000032:analysis; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000032:analysis; D016019:Survival Analysis; D013997:Time Factors; D055815:Young Adult
D015703:Antigens, CD; D018956:CD5 Antigens; D007770:L-Lactate Dehydrogenase; D015260:Neprilysin